Iparomlimab and tuvonralimab
QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.
Overview
Iparomlimab and tuvonralimab (QL1706) uses Qilu's MabPair platform to produce an anti-PD-1 and a short-half-life anti-CTLA-4 antibody in a single manufacturing run. The NMPA approved it in September 2024 for recurrent or metastatic cervical cancer that had failed platinum-based chemotherapy, the first dual checkpoint product approved for this cancer. Phase 3 trials in lung and liver cancers continue.
Two antibodies made in one cell line and given as a fixed mixture: a PD-1 blocker with a normal half-life and a CTLA-4 blocker engineered to clear quickly, so the double checkpoint blockade comes with less of the toxicity seen with ipilimumab combinations. Connects to PD-L1.
1.One arm of Iparomlimab and tuvonralimab binds PD-L1 on the cancer cell.
Compare all products across the US, EU, UK, Japan, China and Australia →
Approvals
| Region | Year | Indication |
|---|---|---|
| CN | 2024 | Recurrent or metastatic cervical cancer after platinum chemotherapy |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Iparomlimab and tuvonralimab" OR ABSTRACT:"Iparomlimab and tuvonralimab" OR TITLE:"QL1706" OR ABSTRACT:"QL1706" OR TITLE:"PSB205" OR ABSTRACT:"PSB205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Iparomlimab and tuvonralimab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBenmelstobart
Shares PD-L1, Immune checkpoint inhibitors and the tags china, nmpa-approved.
- TreatmentIruplinalkib
Shares Qilu Pharmaceutical and the tags china, nmpa-approved.
- TreatmentFlumatinib
Shares the tags china, nmpa-approved.
- TreatmentGumarontinib
Shares the tags china, nmpa-approved.
- TreatmentH101 oncolytic adenovirus
Shares the tags china, nmpa-approved.
- TreatmentInetetamab
Shares the tags china, nmpa-approved.
- TreatmentLinperlisib
Shares the tags china, nmpa-approved.
- TreatmentMecapegfilgrastim
Shares the tags china, nmpa-approved.